• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Molecular Response sells business unit to Crown Bioscience

Molecular Response sells business unit to Crown Bioscience

February 12, 2015
CenterWatch Staff

Molecular Response (MRL), a privately held molecular diagnostic services company based in San Diego, Calif., has sold its PDX business unit to Crown Bioscience, a drug discovery and development service company headquartered in Santa Clara, Calif.

Crown has acquired MRL's PDX bank of several hundred established models currently available for in vivo pharmacology services and several other models under development, with additional acquisition of 8,000 viable human tumors for model development over the next two years from MRL's viable tumor bank of over 140,000 unique cryopreserved tumor samples, and the ability to further develop models from the wider collection. Crown will assume MRL's San Diego-based PDX service operations, and designate the site as a global center of excellence for translational oncology.

MRL will continue operations as a more focused group, maintaining the “living” tumor bank of over 140,000 tumors that now have been proven and accepted by pharmaceutical partners as a rich source of unique subpopulations of cancer for development of high value therapeutic programs.

MRL also will focus on its TargetX drug discovery and development platform that already has resulted in IND-enabling partnered programs to be announced later in the year. Furthermore, MRL will continue its personalized medicine developmental programs currently in prospective clinical trials with key cancer centers.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing